Early 4-1BB agonists failed due to severe liver toxicity. Excalipoint's bispecifics solve this by requiring one arm to bind to a tumor before the other activates T-cells. This localizes the immune response, preventing systemic toxicity and reviving a previously failed mechanism for cancer therapy.
CEO Lei Fang incubated his T-cell engager platform within Leopold Biopharma. When Leopold chose to focus on its other assets, it created an opportunity for Fang to acquire the non-core platform, raise $41M, and launch Excalipoint as a focused, independent company. Corporate refocusing can birth new ventures.
Current therapies use a 'sledgehammer' approach, depleting all B-cells for a total immune reset, limiting use to severe cases. Excalipoint is developing a precise method to deplete only pathogenic B-cells. This targeted approach could be safe enough for less severe conditions, expanding the market.
Excalipoint accelerates R&D via a systematic process combining a pre-built library of molecular tools, deep disease-specific expertise, and a dual China/US clinical strategy for rapid validation. This repeatable 'human algorithm,' now being enhanced with AI, drastically shortens the timeline from concept to clinic.